Skip to main navigation Skip to search Skip to main content

Heparin in malignant glioma: review of preclinical studies and clinical results

  • Rosalie Schnoor
  • , Sybren L N Maas
  • , Marike L D Broekman*
  • *Corresponding author for this work
  • UMC Utrecht Cancer Center
  • University Medical Centre Utrecht

Research output: Contribution to journal › Review article › Academic › peer-review

23 Citations (Scopus)
18 Downloads (Pure)

Abstract

Glioblastoma multiforme (GBM) is the most common primary brain tumor that is invariably lethal. Novel treatments are desperately needed. In various cancers, heparin and its low molecular weight derivatives (LMWHs), commonly used for the prevention and treatment of thrombosis, have shown therapeutic potential. Here we systematically review preclinical and clinical studies of heparin and LMWHs as anti-tumor agents in GBM. Even though the number of studies is limited, there is suggestive evidence that heparin may have various effects on GBM. These effects include the inhibition of tumor growth and angiogenesis in vitro and in vivo, and the blocking of uptake of extracellular vesicles. However, heparin can also block the uptake of (potential) anti-tumor agents. Clinical studies suggest a non-significant trend of prolonged survival of LMWH treated GBM patients, with some evidence of increased major bleedings. Heparin mimetics lacking anticoagulant effect are therefore a potential alternative to heparin/LMWH and are discussed as well.

Original languageEnglish
Pages (from-to)151-6
Number of pages6
JournalJournal of Neuro-Oncology
Volume124
Issue number2
DOIs
Publication statusPublished - 30 Jun 2015
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Heparin in malignant glioma: review of preclinical studies and clinical results'. Together they form a unique fingerprint.

Cite this